SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced the closing of its previously announced underwritten public offering of 8,800,000 shares of its common stock. The net proceeds to Somaxon from the sale of the shares, after the underwriting discount and estimated offering expenses payable by Somaxon, are expected to be approximately $24.8 million.
